PHARMACOLOGY CORE
PHARMACOLOGY CORE
批准号:
8798603
负责人:
DANIEL L GUSTAFSON
金额:
$13.77万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
已结题
起止时间:
至 2016-01-31
关键词:
AnimalsBackBasic ScienceBiochemicalBiologicalBiological AssayBudgetsCancer CenterCancer Center Support GrantCancer ControlChargeClinical ProtocolsClinical ResearchColoradoConsultationsDataDetectionDevelopmentDevelopmental Therapeutics ProgramDoseDrug KineticsEnzyme-Linked Immunosorbent AssayFluorescenceHead CancerHigh Pressure Liquid ChromatographyHormonesHousingInstitutionLiquid substanceMalignant NeoplasmsMalignant neoplasm of lungMeasuresMedicalMethodologyMethodsModelingNeck CancerPharmaceutical PreparationsPharmacologyPharmacology Shared ResourceProceduresResearch DesignResearch PersonnelResearch Project GrantsResourcesSamplingServicesSystemTechnologyTissuesUniversitiesValidationanalytical methodbasecancer preventiondesigninstrumentmathematical analysismemberpharmacokinetic modelpopulation basedpre-clinical researchprogramsquality assuranceresearch studytandem mass spectrometry
中文摘要
目的:药理学共享资源支持科罗拉多大学癌症中心(UCCC)成员的基础和临床研究项目的药代动力学(PK)研究规划和分析。
服务和技术:提供的服务包括:(1)PK研究设计咨询;(2)开发、验证和实施适用于生物液和组织中药物的分析分析;以及(3)分析数据的PK建模和数学分析。药理学共享资源采用的定量分析方法包括UV/Vis和荧光检测高效液相色谱(LC)串联质谱仪,以及其他生化方法(即酶联免疫吸附试验、酶联免疫吸附试验)。PK建模服务包括基于系统的方法(非分区建模)、分区建模、基于生理和基于人群的分析。药理学共享资源包括两台ABI3200线性捕捉器三重四极杆仪器,带有LC系统(Agilent 1200或岛津LC20)和HTC-PAL自动进样器,岛津显著LC系统具有UV/Vis(SPD-M20A)和荧光检测(RF-IOAxl)和冷藏自动进样器(S1L20AC)。会诊:药理学共享资源提供
咨询,帮助几乎没有药理学或PK背景的成员设计合适的实验和分析PK数据。使用:开发治疗计划中的癌症中心成员是药理学共享资源的主要用户;然而,激素相关恶性肿瘤、肺癌、头颈癌和癌症预防与控制计划的成员也是经常使用该资源的用户。药理学共享资源于2007年从安舒茨医学院转移到CSU,从那时起,UCCC成员的使用量每年都在增加,而非UCCC成员的使用量一直保持不变。自2005年最后一次竞争申请以来,药理学共享资源已经支持了来自联盟机构的39名UCCC调查人员和24名非UCCC成员。在过去的两年中,UCCC成员的14个研究项目和10个临床方案得到了支持。管理和财务:该资源由UCCC管理。目前,73.5%的运营预算来自对UCCC成员的收费,这些成员占设施用户的62%。这个
药理学共享资源请求为其运营预算的34%提供11.5万美元的CCSG支持。
英文摘要
Objective: The Pharmacology Shared Resource supports pharmacokinetic (PK) study planning and analysis for both basic and clinical research projects of University of Colorado Cancer Center (UCCC) members.
Services and Technologies: Services offered include: (1) PK study design consultation; (2) Development, validation and implementation of appropriate analytical assays for drugs in biological fluids and tissues; and (3) PK modeling and mathematical analysis of analytical data. Quantitative analytical methods employed by the Pharmacology Shared Resource include UV/Vis and fluorescent detection HPLC, LC tandem mass spectrometry, and other biochemical methodologies (i.e. ELISA, enzymatic). PK modeling services include systems-based approaches (non-compartmental modeling), compartmental modeling, physiologically-based and population-based analyses. The Pharmacology Shared Resource, houses two ABI3200 linear trap triple quadropole instruments with LC systems (Agilent 1200 or Shimadzu LC20) and HTC-PAL autosamplers, a Shimadzu Prominence LC system with UV/Vis (SPD-M20A) and fluorescence detection (RF-IOAxl) and refrigerated autosampler (S1L20AC). Consultation: The Pharmacology Shared Resource provides
consultation to help members with little pharmacology or PK background to design appropriate experiments and analyze PK data. Utilization: Cancer Center members in the Developmental Therapeutics Program are the primary users of the Pharmacology Shared Resource; however, members of the Hormone Related Malignancies, Lung, Head & Neck Cancer and Cancer Prevention & Control Programs are also regular users. The Pharmacology Shared Resource moved to CSU from the Anschutz Medical Campus in 2007 and since then, utilization by UCCC members has increased annually while use by non-UCCC members has remained constant. Since the last competitive application in 2005, the Pharmacology Shared Resource has supported 39 UCCC investigators from across the consortium institutions and 24 non-UCCC members. In the last two years, 14 research projects and 10 clinical protocols from UCCC members have been supported. Management and Finances: This resource is UCCC-managed. Currently, 73.5% of the operating budget comes from charge backs to UCCC members who represent 62% of facility users. The
Pharmacology Shared Resource requests $115K CCSG support for 34% of its operating budget.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Therapeutic targeting of autophagy-dependent cancer
-
批准号:9302316
-
项目类别:
-
资助金额:$49.12万
-
财政年份:2015
-
负责人:DANIEL L GUSTAFSON
-
依托单位:
Therapeutic targeting of autophagy-dependent cancer
-
批准号:9102009
-
项目类别:
-
资助金额:$48.26万
-
财政年份:2015
-
负责人:DANIEL L GUSTAFSON
-
依托单位:
Therapeutic targeting of autophagy-dependent cancer
-
批准号:8928387
-
项目类别:
-
资助金额:$50.23万
-
财政年份:2015
-
负责人:DANIEL L GUSTAFSON
-
依托单位:
PHARMACOLOGY CORE
-
批准号:7229267
-
项目类别:
-
资助金额:$5.11万
-
财政年份:2006
-
负责人:DANIEL L GUSTAFSON
-
依托单位:
Dual Compartmental Targeting of Cancer
-
批准号:7343524
-
项目类别:
-
资助金额:$22.22万
-
财政年份:2005
-
负责人:DANIEL L GUSTAFSON
-
依托单位:
Dual Compartmental Targeting of Cancer
-
批准号:6863593
-
项目类别:
-
资助金额:$24.31万
-
财政年份:2005
-
负责人:DANIEL L GUSTAFSON
-
依托单位:
Dual Compartmental Targeting of Cancer
-
批准号:6998954
-
项目类别:
-
资助金额:$23.75万
-
财政年份:2005
-
负责人:DANIEL L GUSTAFSON
-
依托单位:
Dual Compartmental Targeting of Cancer
-
批准号:7156959
-
项目类别:
-
资助金额:$0.59万
-
财政年份:2005
-
负责人:DANIEL L GUSTAFSON
-
依托单位:
Dual Compartmental Targeting of Cancer
-
批准号:7333230
-
项目类别:
-
资助金额:$22.42万
-
财政年份:2005
-
负责人:DANIEL L GUSTAFSON
-
依托单位:
PREDICTIVE MODELS FOR COMBINATION CANCER CHEMOTHERAPY
-
批准号:6376552
-
项目类别:
-
资助金额:$11.77万
-
财政年份:1998
-
负责人:DANIEL L GUSTAFSON
-
依托单位:
PREDICTIVE MODELS FOR COMBINATION CANCER CHEMOTHERAPY
-
批准号:6172717
-
项目类别:
-
资助金额:$11.53万
-
财政年份:1998
-
负责人:DANIEL L GUSTAFSON
-
依托单位:
PREDICTIVE MODELS FOR COMBINATION CANCER CHEMOTHERAPY
-
批准号:2698167
-
项目类别:
-
资助金额:$7.89万
-
财政年份:1998
-
负责人:DANIEL L GUSTAFSON
-
依托单位:
PREDICTIVE MODELS FOR COMBINATION CANCER CHEMOTHERAPY
-
批准号:2896226
-
项目类别:
-
资助金额:$11.29万
-
财政年份:1998
-
负责人:DANIEL L GUSTAFSON
-
依托单位:
PREDICTIVE MODELS FOR COMBINATION CANCER CHEMOTHERAPY
-
批准号:6513134
-
项目类别:
-
资助金额:$12.03万
-
财政年份:1998
-
负责人:DANIEL L GUSTAFSON
-
依托单位:
PHARMACOLOGY CORE
-
批准号:8465413
-
项目类别:
-
资助金额:$13.73万
-
财政年份:1997
-
负责人:DANIEL L GUSTAFSON
-
依托单位:
MITOMYCIN C SENSITIVITY IN CHO CELL MUTANTS AND HYBRIDS
-
批准号:2106262
-
项目类别:
-
资助金额:$1.52万
-
财政年份:1996
-
负责人:DANIEL L GUSTAFSON
-
依托单位:
MITOMYCIN C SENSITIVITY IN CHO CELL MUTANTS AND HYBRIDS
-
批准号:2106261
-
项目类别:
-
资助金额:$2.86万
-
财政年份:1995
-
负责人:DANIEL L GUSTAFSON
-
依托单位:
MITOMYCIN C SENSITIVITY IN CHO CELL MUTANTS AND HYBRIDS
-
批准号:2106260
-
项目类别:
-
资助金额:$2.37万
-
财政年份:1994
-
负责人:DANIEL L GUSTAFSON
-
依托单位:
PHARMACOLOGY CORE
-
批准号:7584162
-
项目类别:
-
资助金额:$9.46万
-
财政年份:--
-
负责人:DANIEL L GUSTAFSON
-
依托单位:
PHARMACOLOGY CORE
-
批准号:9001278
-
项目类别:
-
资助金额:$13.72万
-
财政年份:--
-
负责人:DANIEL L GUSTAFSON
-
依托单位:
国内基金
海外基金
患者依从性与脑卒中后跌倒风险相关性及“Teach-Back ”护理干预效应研究
-
批准号:2026JJ81464
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:叶婷
-
依托单位:
基于Teach-back药学科普模式的慢阻肺患者吸入用药依从性及疗效研究
-
批准号:2024KP61
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:余丹
-
依托单位:
基于Quench-Back保护的超导螺线管磁体失超过程数值模拟研究
-
批准号:51307073
-
项目类别:青年科学基金项目
-
资助金额:25.0万元
-
批准年份:2013
-
负责人:郭兴龙
-
依托单位: